Pharmaniaga Berhad Third Quarter 2024 Earnings: EPS: RM0.07 (vs RM0.037 loss in 3Q 2023)

Simply Wall St

December 01, 2024

Pharmaniaga Berhad (KLSE:PHARMA) Third Quarter 2024 Results

Key Financial Results

Revenue: RM1.03b (up 16% from 3Q 2023).
Net income: RM101.0m (up from RM49.3m loss in 3Q 2023).
Profit margin: 9.8% (up from net loss in 3Q 2023).
EPS: RM0.07 (up from RM0.037 loss in 3Q 2023).

earnings-and-revenue-growth — KLSE:PHARMA Earnings and Revenue Growth December 1st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Pharmaniaga Berhad Earnings Insights

Looking ahead, revenue is forecast to stay flat during the next 2 years compared to a 7.6% growth forecast for the Healthcare industry in Malaysia.

Performance of the Malaysian Healthcare industry.

The company's shares are up 5.6% from a week ago.

Risk Analysis

Before you take the next step you should know about the 3 warning signs for Pharmaniaga Berhad that we have uncovered.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.